ReviewNature clinical practice. Cardiovascular medicine2009
Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
Review in Nature clinical practice. Cardiovascular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01271985 (Fixed-dose Combination Therapy), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians
Who cites it
12 citing papers in PubMed, 80 citations in OpenAlex.
- The Development of Innovative Dosage Forms of the Fixed-Dose Combination of Active Pharmaceutical Ingredients.Pharmaceutics · 2022Review
- Clinical outcomes in hypertensive patients treated with a single-pill fixed-dose combination of renin-angiotensin system inhibitor and thiazide diuretic.Journal of clinical hypertension (Greenwich, Conn.) · 2018Article
- [Management of different cardiovascular risk factors with a combination tablet (polypill)].Herz · 2018Review
- Observational
- Article
- Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study.PloS one · 2015Article
- Global perspective on acute coronary syndrome: a burden on the young and poor.Circulation research · 2014Article
- Efficacy and tolerability of fixed dose combination of metoprolol and amlodipine in Indian patients with essential hypertension.Journal of mid-life health · 2013Article
- Qi-shen-yi-qi dripping pills for the secondary prevention of myocardial infarction: a randomised clinical trial.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Novel treatments for cardiovascular disease prevention.Cardiovascular therapeutics · 2012Review
- Secondary prevention strategies for coronary heart disease.Journal of thrombosis and thrombolysis · 2010Review
- Epidemiology of cardioprotective pharmacological agent use in stable coronary heart disease.Indian heart journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic heart disease and stroke are the leading causes of death worldwide. A large proportion of individuals at high 10-year risk of a cardiovascular event live in low-income and middle-income countries, and the large majority of all cardiovascular events occur in developing countries. A large amount of evidence supports the use of pharmacological treatment for the prevention of cardiovascular death in this population, including antiplatelet drugs, beta blockers, lipid-lowering agents and angiotensin-converting-enzyme inhibitors. However, the efficacy of cardiovascular prevention is hampered by several problems, including inadequate prescription of medication, poor adherence to treatment, limited availability of medications and unaffordable cost of treatment. Here we examine the use of fixed-dose combination therapy (a 'polypill'), and how this therapy could improve adherence to treatment, reduce the cost and improve treatment affordability in low-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.